Bioventus Inc. (BVS) Stock Forecast
BVS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $17.60 average of analyst targets
- Upside to target
- +32.3% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.17
- 52-week range
- $6.53 – $15.26
BVS analyst ratings
5 analystsNumber of analysts at each rating.
BVS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BVS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.16 | $0.13 | $0.18 | $0.15 | +6.7% | 5 |
| Current fiscal year (2026) | $0.78 | $0.77 | $0.79 | $0.68 | +14.4% | 5 |
| Next fiscal year (2027) | $0.92 | $0.88 | $0.96 | $0.78 | +18.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BVS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $149.5M | $148.4M | $150.7M | +7.8% | 5 |
| Current fiscal year (2026) | $604.8M | $602.0M | $606.0M | +6.5% | 5 |
| Next fiscal year (2027) | $645.6M | $641.0M | $656.0M | +6.7% | 5 |
BVS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BVS revenue: reported and forecast
BVS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.18 | $0.18 | $0.18 | $0.17 | $0.16 | −9.1% | 0 up · 3 down |
| Current fiscal year (2026) | $0.78 | $0.78 | $0.78 | $0.78 | $0.78 | −0.3% | 0 up · 1 down |
| Next fiscal year (2027) | $0.91 | $0.91 | $0.91 | $0.91 | $0.92 | +1.3% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BVS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BVS beat in 12 of 12.
What analysts expect from BVS
5 analysts cover Bioventus; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.60, 32.3% above the latest close of $13.30. Analysts expect earnings of $0.78 per share for 2026, +14.4% from a year earlier. For 2027 the average estimate is $0.92 per share on revenue of $645.6 million. Bioventus beat the EPS estimate in 12 of the last 12 quarters.
Related: BVS income statement, BVS key metrics, BVS chart. See the BVS stock overview for the latest quote and news.
BVS forecast FAQ
What is Bioventus's price target?
The average analyst price target for Bioventus is $17.60, 32.3% above the latest close of $13.30.
Is Bioventus a buy, hold or sell?
Of 5 analysts covering Bioventus, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bioventus's EPS forecast?
Analysts forecast $0.78 per share for 2026 (range $0.77 to $0.79); for 2027 the estimate is $0.92.
What is Bioventus's revenue forecast?
The average revenue estimate for 2026 is $604.8 million, growth of 6.5%; for 2027 it is $645.6 million.
When does Bioventus report earnings?
Bioventus is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.17.
Does Bioventus usually beat earnings estimates?
Bioventus reported EPS at or above the analyst estimate in 12 of the last 12 quarters.